Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

被引:45
作者
Wu, ZC
Fraley, ME
Bilodeau, MT
Kaufman, ML
Tasber, ES
Balitza, AE
Hartman, GD
Coll, KE
Rickert, K
Shipman, J
Shi, B
Sepp-Lorenzino, L
Thomas, KA
机构
[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA
关键词
D O I
10.1016/j.bmcl.2003.12.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
3,7-Diaryl substituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:909 / 912
页数:4
相关论文
共 18 条
  • [1] SYNTHESIS AND SECRETION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR BY HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS
    ADAMIS, AP
    SHIMA, DT
    YEO, KT
    YEO, TK
    BROWN, LF
    BERSE, B
    DAMORE, PA
    FOLKMAN, J
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 193 (02) : 631 - 638
  • [2] Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR
    Bilodeau, MT
    Cunningham, AM
    Koester, TJ
    Ciecko, PA
    Coll, KE
    Huckle, WR
    Hungate, RW
    Kendall, RL
    McFall, RC
    Mao, XZ
    Rutledge, RZ
    Thomas, KA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (15) : 2485 - 2488
  • [3] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents
    Bilodeau, MT
    Fraley, ME
    Hartman, GD
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 737 - 745
  • [4] Boyer Stephen J., 2002, Current Topics in Medicinal Chemistry, V2, P973, DOI 10.2174/1568026023393273
  • [5] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [6] The role of VEGF and thrombospondins in skin angiogenesis
    Detmar, M
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 24 : S78 - S84
  • [7] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [8] Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors:: Improvements in physical properties enhance cellular activity and pharmacokinetics
    Fraley, ME
    Rubino, RS
    Hoffman, WF
    Hambaugh, SR
    Arrington, KL
    Hungate, RW
    Bilodeau, MT
    Tebben, AJ
    Rutledge, RZ
    Kendall, RL
    McFall, RC
    Huckle, WR
    Coll, KE
    Thomas, KA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (24) : 3537 - 3541
  • [9] Synthesis and initial SAR studies of 3,6-disubstituted pyrazolol[1,5-a]pyrimidines:: A new class of KDR kinase inhibitors
    Fraley, ME
    Hoffman, WF
    Rubino, RS
    Hungate, RW
    Tebben, AJ
    Rutledge, RZ
    McFall, RC
    Huckle, WR
    Kendall, RL
    Coll, KE
    Thomas, KA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (19) : 2767 - 2770
  • [10] The angiogenic pathway 'vascular endothelial growth factor/flk-I (KDR)-receptor' in rheumatoid arthritis and osteoarthritis
    Giatromanolaki, A
    Sivridis, E
    Atanassou, N
    Zois, E
    Thorpe, PE
    Brekken, RA
    Gatter, KC
    Harris, AL
    Koukourakis, IM
    Koukourakis, MI
    [J]. JOURNAL OF PATHOLOGY, 2001, 194 (01) : 101 - 108